These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 16396697)

  • 1. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
    Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
    Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH
    J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
    Brocq O; Plubel Y; Breuil V; Grisot C; Flory P; Mousnier A; Euller-Ziegler L
    Presse Med; 2002 Nov; 31(39 Pt 1):1836-9. PubMed ID: 12496713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.
    Laas K; Peltomaa R; Kautiainen H; Leirisalo-Repo M
    Clin Rheumatol; 2008 Jul; 27(7):927-32. PubMed ID: 18414967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
    Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K; Koike T
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.
    Finckh A; Simard JF; Duryea J; Liang MH; Huang J; Daneel S; Forster A; Gabay C; Guerne PA
    Arthritis Rheum; 2006 Jan; 54(1):54-9. PubMed ID: 16385495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
    Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
    Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns of anti-TNF agents in Italy: an observational study.
    Punzi L; Matucci Cerinic M; Cantini F; Bagnato G; Fiocco U; Ferri C; Bombardieri S
    Reumatismo; 2011 Mar; 63(1):18-28. PubMed ID: 21509346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
    Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
    Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.